BPI 21668
Alternative Names: BPI-21668Latest Information Update: 26 Apr 2022
At a glance
- Originator Betta Pharmaceuticals Co Ltd
- Class Antineoplastics; Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Jan 2022 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (PO) (NCT05341570)
- 07 Jan 2022 Betta Pharmaceutical plans a phase I trial for Solid tumours in China (Betta Pharmaceutical pipeline,
- 07 Jan 2022 Preclinical trials in Solid tumours in China (PO) (Betta pharmaceutical pipeline,